Bruce Mayer, along with CCAM graduate student Adam Lafontaine and faculty colleague Kazuya Machida, submitted a US patent application, ” SH2 domain-based prognostic biomarker for chronic lymphocytic leukemia (CLL). “ This application grew out of studies that aimed to correlate quantitative patterns of binding sites for Src Homology 2 (SH2) domains in tumor cells with clinical outcomes, such as likelihood of disease progression and response to therapy.